• Contact us
Saturday, November 21, 2026
Register
Login
European Press
ADVERTISEMENT Handpicked deals on Amazon Discover useful products selected for our readers. Explore deals ›
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Media
  • Lifestyle
  • Video
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Media
  • Lifestyle
  • Video
No Result
View All Result
European Press
No Result
View All Result

Experimental pancreatic cancer drug doubles survival time in trial

21 November 2026
in Health
Reading Time: 3 mins read
A A
Experimental pancreatic cancer drug doubles survival time in trial
ShareShareShareShareShare


NEWYou can now listen to Fox News articles!
Pairing an experimental pill with standard chemotherapy shrank tumors or halted growth in most patients with advanced pancreatic cancer, according to early clinical trial results presented Friday at a major international cancer conference.The findings, shared at the EORTC-NCI-AACR Symposium in Barcelona, come from a phase ½ trial testing a daily oral medication called daraxonrasib, along with two standard intravenous chemotherapy drugs, gemcitabine and nab-paclitaxel.The trial focused on 61 patients whose pancreatic cancer had already spread to other organs and who had not yet received treatment for their advanced disease.PANCREATIC CANCER PATIENT BEN SASSE SEES ‘MASSIVE’ TUMOR REDUCTION WITH EXPERIMENTAL NEW DRUGPancreatic cancer is notoriously difficult to treat because more than half of patients are diagnosed after the disease has already spread, research shows.In major clinical trials for metastatic pancreatic cancer, chemotherapy alone shrinks tumors in about 23% to 42% of patients, but the disease typically begins growing again after five to six months, and most patients survive between 8 and 11 months. Combining an experimental daily pill called daraxonrasib with standard chemotherapy shrank tumors or stopped cancer growth in 90.2% of patients with untreated, advanced pancreatic cancer. (iStock)According to National Cancer Institute data, only about 3% of patients with distant-stage disease live five years past diagnosis.In the new study, which tracked patients for a median follow-up of 18 months, tumors shrank in 60.7% of cases, including 8.2% where they disappeared entirely on scans. Overall, the combination stopped tumor growth in 90.2% of participants.FDA APPROVES ONCE-DAILY PILL FOR DEADLY CANCER AFTER PATIENTS’ SURVIVAL RATES NEARLY DOUBLEPatients went a median of 12.8 months before their cancer worsened, almost double the timeframe typically seen with standard chemotherapy, and 76.6% were still alive at the one-year mark, the study found.”We are now seeing not only substantial tumor shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year,” study lead Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, said in a press release. Most side effects, including rash, diarrhea, fatigue and low blood cell counts, were manageable with standard care, and only 5% of patients stopped treatment due to daraxonrasib. (iStock)More than 90% of pancreatic cancers are driven by a faulty gene called RAS, which allows tumors to keep growing. Daraxonrasib is designed to turn off that growth signal, something scientists long thought was impossible to fix with medication.Dr. Elena Garralda, chair of the symposium and co-director of the clinical research program at the Vall d’Hebron Institute of Oncology in Spain, who was not involved in the research, said the results show that RAS-targeted drugs can be combined with existing treatments at the start of treatment to potentially achieve longer-lasting benefits.CLICK HERE FOR MORE HEALTH STORIESSide effects included rash, diarrhea, fatigue and low blood cell counts linked to chemotherapy, most of which were manageable with standard care.Only 5% of patients stopped treatment because of side effects tied to daraxonrasib.TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZResearchers emphasized that the findings carry some limitations.Because this was an early-phase, single-group study involving 61 people, all participants received the experimental combination. Without a direct comparison group of patients receiving standard chemotherapy alone, doctors cannot yet confirm how much better the new regimen performs or whether it definitively extends overall survival. Researchers are now running a larger, randomized Phase 3 trial to directly compare the new treatment against standard chemotherapy. (iStock)The findings also apply strictly to metastatic pancreatic cancer, even though RAS mutations drive several other cancers, including certain lung, colorectal and gynecological cancers. Separate studies would be needed to test whether the combination works in those diseases.CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTERThe trial was funded by Revolution Medicines, the California-based developer of daraxonrasib.CLICK HERE TO DOWNLOAD THE FOX NEWS APPTo determine whether these early findings translate into a durable survival benefit, researchers have launched a larger, randomized Phase 3 trial, called RASolute-303, which directly compares daraxonrasib — both on its own and combined with chemotherapy — against standard chemotherapy alone. Khloe Quill is a lifestyle writer with Fox News Digital. She and the lifestyle team cover a range of story topics including food and drink, travel, and health. 

Credit: Source link

Previous Post

Rodeo Drive holiday lighting celebration marks 50 years

Next Post

Wordle today: The answer and hints for November 21, 2026

Recommended

Gritty road trip was enough to give Knicks back their mojo

Gritty road trip was enough to give Knicks back their mojo

21 November 2026

It can help to get away.  The Knicks left for their four-game road trip a bit unsettled, with questions circling...

Wordle today: The answer and hints for November 21, 2026

Wordle today: The answer and hints for November 21, 2026

21 November 2026

Today's Wordle answer should be easy to solve if you're a cardiologist.If you just want to be told today's word,...

Experimental pancreatic cancer drug doubles survival time in trial

Experimental pancreatic cancer drug doubles survival time in trial

21 November 2026

NEWYou can now listen to Fox News articles! Pairing an experimental pill with standard chemotherapy shrank tumors or halted growth...

Rodeo Drive holiday lighting celebration marks 50 years

Rodeo Drive holiday lighting celebration marks 50 years

21 November 2026

Even the palm trees get dressed up for the holidays in Beverly Hills.  The annual Rodeo Drive Holiday Lighting Celebration...

Datenschutzinformationen

Disclaimer  Privacy Policy – EU  Imprint 

Join European Press

Contact us

What’s New Here!

  • Gritty road trip was enough to give Knicks back their mojo
  • Wordle today: The answer and hints for November 21, 2026
  • Experimental pancreatic cancer drug doubles survival time in trial
  • Rodeo Drive holiday lighting celebration marks 50 years

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

© 2026 European Press. All rights reserved.

European Press
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
No Result
View All Result
  • News
  • Business
  • Tech
  • Sport
  • Health
  • Media
  • Lifestyle
  • Video

© 2026 European Press. All rights reserved.

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?